Bank Pictet & Cie Europe AG Takes $206,000 Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Bank Pictet & Cie Europe AG bought a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 4,692 shares of the company’s stock, valued at approximately $206,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GPCR. Griffin Asset Management Inc. bought a new stake in shares of Structure Therapeutics in the 3rd quarter valued at about $634,000. Exchange Traded Concepts LLC grew its holdings in shares of Structure Therapeutics by 191.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 41,101 shares of the company’s stock worth $1,804,000 after acquiring an additional 27,019 shares during the period. SG Americas Securities LLC purchased a new position in shares of Structure Therapeutics during the 3rd quarter worth approximately $367,000. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Structure Therapeutics by 28.5% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 17,651 shares of the company’s stock worth $693,000 after acquiring an additional 3,918 shares during the period. Finally, Perceptive Advisors LLC purchased a new position in shares of Structure Therapeutics during the 2nd quarter worth approximately $1,369,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Price Performance

Shares of GPCR opened at $38.07 on Thursday. The firm has a market capitalization of $1.77 billion, a PE ratio of -49.44 and a beta of -3.53. Structure Therapeutics Inc. has a 1-year low of $26.61 and a 1-year high of $75.02. The company’s fifty day moving average price is $39.59 and its 200-day moving average price is $39.84.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. As a group, research analysts anticipate that Structure Therapeutics Inc. will post -0.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on GPCR shares. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Morgan Stanley started coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. Finally, JMP Securities decreased their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $87.83.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.